Triathlete Diagnosed with Stage 4 Lung Cancer Despite Never Smoking
Dave Nitsche, a 57-year-old triathlete and non-smoker, was diagnosed with stage 4 lung cancer at age 49 after experiencing sudden vision loss. Despite an initial prognosis of 1-2 years, he has significantly surpassed this outlook, attributing his survival to targeted therapies and his active lifestyle. His cancer, which had metastasized to multiple organs, was discovered following his sudden vision impairment in late 2019.
Dave Nitsche, a 57-year-old project manager and active triathlete, was diagnosed with stage 4 lung cancer at age 49, despite being a non-smoker with no family history of the disease. Nitsche regularly competed in ultra-running and triathlon events, including Ironmans, and maintained an active lifestyle.
The first symptom Nitsche experienced was sudden blurry vision in one eye in late 2019, shortly before his 50th birthday. Straight objects appeared wavy, and he eventually lost vision completely in that eye. After visiting an optometrist, he was sent to the hospital for ultrasounds. Three weeks later, he received a diagnosis of stage 4 lung cancer that had metastasized to his eye, bones, liver, kidneys, and brain. Due to significant fluid buildup and pressure, his eye was removed and replaced with a prosthetic.
Upon diagnosis, Nitsche was given a prognosis of 1 to 2 years to live. He felt a shock, noting that other than vision loss, he felt normal. Due to the widespread nature of the cancer, he was informed that traditional treatments like chemotherapy or radiation offered no chance at that point.
Instead, Nitsche pursued targeted therapies designed to block specific cancer-driving molecules. He initially took Gilotrif (afatinib), an oral medication, and later Tagrisso (osimertinib) to target brain tumors. He remained on Tagrisso for six years, far exceeding his original life expectancy. He has since undergone radiation for a small brain cancer area and is currently on Rybrevant (amivantamab), an antibody therapy that blocks cancer growth signals.
Nitsche attributes his survival beyond the initial prognosis to the timing and effectiveness of these targeted drugs, alongside his high VO2 max from his active lifestyle. All his treatments have been covered by Canada's national health insurance. He continues to live with the reality of his diagnosis, stating he is seven years into his journey.
According to Business Insider, Nitsche's case highlights the complexities of lung cancer, which can affect individuals with no traditional risk factors.
